Intermediate High Risk (IHR) PE: The value of a PE Lysis Team (PELT)
C. Carter (London, United Kingdom), T. Mason (London, United Kingdom), B. Lams (London, United Kingdom), B. Mukherjee (London, United Kingdom), N. Karunanithy (London, United Kingdom), B. Hunt (London, United Kingdom), K. Breen (London, United Kingdom), A. West (London, United Kingdom)
Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Carter (London, United Kingdom), T. Mason (London, United Kingdom), B. Lams (London, United Kingdom), B. Mukherjee (London, United Kingdom), N. Karunanithy (London, United Kingdom), B. Hunt (London, United Kingdom), K. Breen (London, United Kingdom), A. West (London, United Kingdom). Intermediate High Risk (IHR) PE: The value of a PE Lysis Team (PELT). 3582
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pulmonary Embolism Lysis Team (PELT): Guiding thrombolysis in Sub-Massive PE (SMPE) Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017
Using Step Count to Enhance Daily Physical Activity in PH, a pilot-study (STEP in PH). Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Selection of patients from Pulmonary Rehabilitation (PR) to Disease Management (DM) programmes Source: International Congress 2017 – Latest insights into the management of chronic lung diseases Year: 2017
Effects of Pulmonary Rehabilitation (PR) on Exercise Capacity (EC) and Quality of Life (QOL) in Indian Patients with Severe COPD Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD Year: 2017
Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Patient and Public Involvement (PPI) in TANDEM: A Tailored intervention for ANxiety and DEpression Management in COPD Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017
A service evaluation of the accuracy of the Gold Standard Framework Proactive Indicator Guidance (GSF PIG) in predicting 12 month mortality in patietns with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD). Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
Prevalence and Risk Factors of Asthma and Allergy-Related Diseases among Adolescents (PERFORMANCE) study: rationale and methods Source: ERJ Open Res, 4 (2) 00034-2018; 10.1183/23120541.00034-2018 Year: 2018
Imaging (Workshop) Source: Year: 2016
Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO Source: Virtual Congress 2021 – COVID-19 acute respiratory distress syndrome Year: 2021
Clinical Impact of 2 types of Mandibular Retention Devices (MRD) - Narval CADCAM vs Narval nonCADCAM – on OSA: ESTAMPS STUDY Source: International Congress 2018 – Treatments that can serve as an alternative to positive airway pressure (PAP) Year: 2018
Feasibility and Validation Testing of the Walk.Talk.Track. (WTT) App for Remote Monitoring of the Six Minute Walk Test (6MWT) in Pulmonary Arterial Hypertension (PAH). Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021
Role of the PE rule-out criteria (PERC) in patients with suspected pulmonary embolism (PE) in a UK District General Hospital Source: International Congress 2016 – Acute pulmonary embolism Year: 2016
Late Breaking Abstract - Patient Reported Outcomes (PRO) Correlate Better with Intra-Breath than with Whole-Breath FOT Parameters. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
Sincope is a risk marker in Pulmonary Embolism (PE) with a low risk clinical profile (sPESI:0) Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019
Knowing asthma in adolescentes from Uruguaiana: The Global Asthma Network (GAN) Source: International Congress 2019 – Aetiology and management of childhood respiratory infections, primary ciliary dyskinesia and asthma Year: 2019
Asthma Control and the Influence of Valved Holding Chamber (VHC) Type: Results from a Real World, Retrospective Study Source: International Congress 2017 – Bronchial asthma management Year: 2017
Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB) Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010
Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network Source: Eur Respir J, 51 (1) 1701937; 10.1183/13993003.01937-2017 Year: 2018
Development and first validation of the COugh Assessment Test (COAT) Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017